days in SCD. 16, 20 Considering that during normal red cell turnover, the monocyte-macrophage system absorbs and releases 25 mg of iron from senescent erythrocytes each day, this rate should be dramatically increased in SCD. 21, 22 Third, in SCD, a significant fraction of the hemolysis takes place intravascularly, and some of the resulting hemoglobin and heme is taken up by circulating monocytes.
In the present study, we analyzed the SCD transcriptome to identify genes that are highly coregulated in patients categorized by their iron-regulated gene expression profile. Next, we showed that SCD patients with the Q248H ferroportin gene mutation, which is reported to increase monocyte macrophage intracellular iron levels, have more inflammation than SCD patients with wild-type ferroportin. Finally, to underline the importance of these findings, we showed the association of inflammation with mortality in a large cohort of SCD patients.
Methods

Subjects
The National Heart, Lung, and Blood Institute's Institutional Review Board approved the protocols. All subjects provided written informed consent. All patients presented in this article are selected from a long-term registry study evaluating the prevalence of secondary pulmonary hypertension and mortality in SCD (ClinicalTrials.gov identifier NCT00011648). We refer to the group of patients included in this study as the NIH (National Institutes of Health) SCD cohort. Inclusion criteria for the sickle cell individuals were age ≥18 years and chromatographic diagnosis of SCD. Only outpatients in stable condition were included; patients who had had a vaso-occlusive crisis within the previous 2 weeks or an episode of acute chest syndrome within the previous 4 weeks were evaluated at a later time. For more detailed description, refer to the Online Data Supplement.
CRP and Interleukin-6 Protein Measurements
CRP was measured by the NIH Clinical Center Department of Laboratory Medicine using nephelometry. All samples were directly measured at inclusion of the patient in the NIH SCD cohort. The lower limit of detection was 0.2 mg/dL. Interleukin-6 (IL-6) was measured using a high sensitivity IL-6 ELISA kit (eBioscience, San Diego, CA) according to the manufacturer's directions. IL-6 was measured on frozen plasma samples in a random group of 161 patients of the NIH SCD cohort (ClinicalTrials.gov identifier NCT00011648).
Messenger RNA Profiling
To assess the role of proinflammatory profile in SCD, whole PBMC transcriptome was evaluated in 24 adult SCD patients and 10 healthy controls. We prospectively defined a group of 33 genes, previously reported to be regulated by iron, as a gene signature for intracellular iron status, which we refer to as the predefined iron-regulated geneset (Online Table I ). To explore the correlation within patient and control samples, we applied unsupervised 2-way hierarchical clustering analysis on this predefined iron-regulated gene-set.
Real-Time Quantitative PCR Analysis
Quantitative real-time PCR (Q-PCR) assays were performed on 10 differentially expressed genes with the use of gene-specific double fluorescently labeled probes. Samples were analyzed in duplicate and the CT values obtained were normalized to the housekeeping gene RNA18S5. Comparative CT (ΔΔCT) was used to achieve the relative fold change in gene expression between the high iron group and medium/low iron group.
Ferroportin Q248H Genotyping
Ferroportin Q248H genotyping was performed as described in the Online Data Supplement. In short, exon 6 of ferroportin was amplified by PCR from genomic DNA using a set of primers encompassing portions of the introns that flank the exon. The resulting DNA fragments were resolved on 2.5% agarose gel and detected with ethidium bromide staining. Ferroportin Q248H mutations included the GT and TT genotype. Hepcidin decreases ferroportin expression. The ferroportin Q248H protein is more resistant to hepcidin than wildtype ferroportin. Because hepcidin levels are strongly associated with ferritin levels in SCD, we selected only cases and controls with a ferritin level <1000 ng/mL. IL-6 data were log 10 transformed to improve normality, and between-group differences were tested using unpaired and paired Student t-test.
Mortality Analysis
The association of CRP with mortality was studied using data from 412 subjects with SCD from a larger cohort for whom follow-up information and CRP levels were available (ClinicalTrials.gov identifier: NCT00011648). Patients were divided into 3 groups: a high CRP group at the 75th percentile level of CRP which was 0.8 mg/ dL, a low CRP group with a CRP level under the limit of detection of the assay, and an intermediate group which had CRP level in between 0.8 mg/dL and 0.2 mg/dL. Subjects who were not known to be dead were censored at the date of last contact with study staff or at a follow-up time of 100 months. The cumulative incidence curves of mortality for the 3 CRP groups were estimated by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazards regression models were used to examine the association of CRP although adjusting for other factors previously published to be associated with mortality: age, sex, N-terminal prohormone of brain natriuretic peptide, tricuspid regurgitant jet flow velocity, glomerular filtration rate (BSA-adjusted glomerular filtration rate as estimated by the Modification of Diet in Renal Disease formula), white blood cell count, transferrin, systolic blood pressure, and fetal hemoglobin.
Statistics
Continuous data are expressed as medians with corresponding interquartile ranges. Between-group differences were tested with the Mann-Whitney U or Kruskal-Wallis test or otherwise as stated. Baseline tables were not tested for statistical differences. Categorical data are presented as percentages or fractions. Differences between groups of categorical data were tested with the χ 2 test. When needed, parameters were log10 transformed to normalize their distributions. For correlation studies, Spearman's rank correlation coefficient was determined otherwise as stated. P values of ≤0.05 were considered statistically significant. Statistical analyses were performed using SPSS Statistics 17.0.2 (IBM, USA) and SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
Subgroup of SCD Patients Has High PBMC Expression of Iron-Regulated Genes
To categorize patients by iron-regulated gene expression, we profiled the PBMC transcriptome of 24 patients with SCD in steady state (median age 36 years) and also 10 healthy controls of similar ethnicity (median age 37 years). 23 A predefined set of 33 iron-regulated genes (see Online Table I ) was used to classify subjects according to their characteristics of iron-regulated gene expression. Two-way hierarchical clustering of the 34 included subjects and 33 iron-regulated genes yielded 3 clusters Figure 1 ). Detailed laboratory characteristics of the subjects in these clusters are shown in Online Table II . Serum levels of bilirubin were associated with the expression of heme oxygenase-1, the gene for the enzyme that cleaves heme to the bilirubin precursor biliverdin (Spearman ρ=0.387, P=0.034) and also with the rank of the cluster in which patients and controls were grouped based on the expression of their iron-regulated genes (ordered from low to high iron, ρ=0.358; P=0.044). One of the sources of free intracellular iron in monocytes/macrophages in SCD is likely iron released from heme by heme oxygenase-1, the first committed biochemical step in conversion of heme to bilirubin. 24 The group with the highest differential expression of iron-regulated genes contained only SCD patients. Thus, clustering by iron-regulated genes readily identifies a subgroup of patients with internally consistent and highly differentially expressed iron genes.
Expression of Iron-Regulated Genes Is Associated With Coexpression of Genes Involved in Inflammasome Formation
In our gene discovery experiment, we identified other genes that were differentially expressed among the 3 groups and found 98 genes which were consistently and significantly differentially expressed. Using Ingenuity Pathway Analysis, we found that the majority of involved canonical pathways were associated with innate immunity and inflammasome formation (each P<0.004; Table 1 ). Highly expressed inflammasome and innate immunity-related genes in the high iron-regulated gene expression patients included TLR4, TLR7, TLR8, NLRP3, NLRC4, PRKCA, CLEC7A and CASP1, IL-1, and IL-18. To help validate these results, we tested 10 representative-regulated genes found on microarray with confirmatory Q-PCR, and the 2 results were strongly correlated (R=0.72, P=0.023; Figure 2A and 2B). One of the most highly differentially expressed genes between the 3 iron clusters was toll-like receptor 4 (TLR4) gene. The expression of the TLR4 gene was highly correlated to ferritin light chain (FTL) gene expression in both patients (R=0.930, P<0.001) and controls (R=0.943, P=0.026; Figure 2C ). TLR4 activation results in the secretion of several proinflammatory cytokines, such as IL-6, by monocytes/macrophages and plays a key role in innate immunity, 25, 26 which prompted us to also measure IL-6 gene expression by Q-PCR, as a surrogate marker of TLR4 activation. In SCD patients, IL-6 expression correlated closely to expression of both TLR4 (R=0.897, P<0.001) and FTL (R=0.909, P<0.001).
In concordance with the clustering of SCD patients in the high iron group, each of the 3 genes was expressed over 200-fold more highly in SCD patients than in controls (P<0.001; Figure 2D ). Together, these results suggest that several iron-regulated genes are expressed in SCD patients at much higher levels than in controls and are coexpressed with genes involved in inflammation and especially members of the inflammasome pathway.
IL-6 Is Associated With CRP in SCD
Because of the association of the iron-regulated genes with genes involved in inflammation, we planned further analysis of inflammation in the NIH SCD cohort. In this cohort, we measured plasma levels of IL-6 in a subgroup of 161 consecutive patients that had frozen plasma samples available. Detailed baseline characteristics of the patients are provided in the Online Table   III . Plasma levels of IL-6 were correlated to CRP (Spearman ρ=0.496; P<0.001), endothelin-1 (ρ=0.396; P<0.001), leukocyte count (ρ=0.262; P=0.001), and monocyte count (ρ=0.191; P=0.017). IL-6 plasma level was negatively correlated with serum transferrin (ρ=−0.244; P=0.006). These results were qualitatively similar when restricted to homozygous sickle cell anemia (HbSS) patients (n=116). The strong correlation between CRP and IL-6 in SCD patients is consistent with published evidence that hepatic cell expression of CRP is induced principally by IL-1 and IL-6 in addition to recently found IL-17. 27 Thus, CRP expression is a useful and well accepted clinical marker of IL-6 and associated pathways. These results were qualitatively similar when restricted to HbSS patients.
Relation Between Intracellular Iron and Inflammation in SCD
The common genetic mutation of African hemochromatosis, the Q248H mutation in the cellular iron exporter ferroportin, results in intracellular iron accumulation in monocytes and macrophages. 28 We hypothesized that this defect in iron trafficking in monocytes/macrophages would promote the crosstalk between intracellular iron and inflammatory activation marked by IL-6 and CRP expression.
The patients who were included in our gene expression study had ferroportin Q248H mutation status available and therefore were used to explore the association between this mutation and inflammation. Indeed, patients with a ferroportin Q248H mutation (GT or TT genotype, n=5) had significantly higher plasma levels of CRP than patients with wild-type ferroportin alleles (GG genotype, n=19; P<0.05), and also log 10 IL-6 trended higher (P=0.08; Figure 3A and 3B). We further confirmed this result in a case-control study based on patients from the NIH SCD cohort. In the NIH SCD cohort, ferroportin Q248H status was available in 359 patients, and of these, 28 (5.3%) had the Q248H ferroportin variant. Fourteen SCD patients with a ferroportin Q248H mutation had a ferritin level <1000 mg/dL (n=14, HbSS=10, HbSC=4) and were included as cases in the case-control study. These cases were compared with SCD patients with wild-type ferroportin Q248H status matched for ferritin and genotype. Again, we found that plasma levels of IL-6 and CRP were significantly lower in the cases than in the controls (P<0.05; Figure 3C and 3D). We found qualitatively similar trends in subgroup analysis restricted to HbSS patients only (P=0.07 and P=0.17).
Inflammation Is Associated With Mortality
Association of CRP with mortality was examined using data from 412 subjects from another cohort (ClinicalTrials.gov identifier: NCT00011648) for whom follow-up information and CRP levels were available. Patients were divided into high, intermediate, and low CRP groups. Detailed baseline characteristics of the patients are provided in the Online Table IV . Kaplan-Meier survival curves show that mortality rate significantly increased according to CRP group (P=0.0017; Figure 4 and Table 2 ). Univariate regression showed that each increase in log 10 -transformed CRP was associated with a hazard ratio of 3.0 for early death (95% confidence interval, 1.7-5.2; P<0.0001). This mortality effect was even more prominent when the population was restricted to patients with sickle cell anemia (HbSS; hazard ratio, 3.4; 95% confidence interval, 1.9-6.3; P<0.0001). We did not evaluate the CRP-mortality relationship in the smaller subgroup of non-HbSS patients alone because of the small group size and low number of events.
Five-year mortality percentages for the low, intermediate, and high CRP groups were, respectively, 12.4%, 20.5%, and 25.8%. CRP was independently associated with mortality in a Cox proportional hazards regression model after adjustment for other covariates previously published as associated with mortality. This adds to previous published models, which have reproducibly identified renal dysfunction 8, [30] [31] [32] and higher tricuspid regurgitation velocity as predictors of death in SCD. [33] [34] [35] [36] Polytransfused patients had higher serum ferritin and CRP levels compared with nonpolytransfused patients (data not shown). Exclusion of polytransfused patients did not change the results of the mortality analysis. Surprisingly, the survival of polytransfused patients did not differ significantly from nonpolytransfused patients (data not shown). Analyzing polytransfused patients only in a Cox proportional hazards regression model showed that CRP was significantly associated with mortality in this group as well (hazard ratio, 3.7; 95% confidence interval, 1.5-8.7; P=0.003).
The observation of an independent relationship of CRP with mortality in SCD provides strong new support for an important role of inflammation in SCD pathophysiology.
Discussion
The results of this study show that (1) iron-regulated genes, such as FTL, are highly upregulated in SCD PBMCs compared with healthy control PBMC; (2) upregulation of iron-regulated genes is associated with genes involved in inflammation and innate immunity, such as TLR4 and IL-6; (3) genetic evidence for a causal relationship between intracellular PBMC iron and inflammation suggested by higher levels of CRP and IL-6 in patients with the ferroportin Q248H mutation compared with patients with wild-type ferroportin; and (4) the inflammatory marker CRP is independent predictor of early mortality in SCD.
The clustering of SCD patients exclusively in the high iron group is consistent with the hypothesis that PBMC intracellular iron trafficking is high in SCD patients. This thesis is supported strongly by the 2 log difference in FTL expression between SCD patients and controls in the Q-PCR assay. The transcriptional and post-transcriptional regulation of FTL gene expression is well characterized and mainly dependent on intracellular free iron. 37 By combining a set of 33 genes that are described to be regulated by iron, we increased the power to discover genes associated with the common regulating factor, that is, intracellular iron. Therefore, it is likely that the clustering and the subsequent identification of associated canonical pathways are a relevant reflection of intracellular iron exposure.
Our findings in the gene discovery assay provide the most comprehensive evidence to date for a role of the inflammasome in SCD as suggested by Wanderer. 38 Many of the genes (R=0.943, P=0.026) , although mean expression of both genes was much higher in patients than in controls (P<0.001). TLR4 was also highly correlated to ALDH1A1, GAPDH, SAT2, and HMOX expression (data not shown). To get a better impression of actual gene expression, x and y axis are reversed and originate 20 ΔCT. D, Bars show the fold change in expression of selected genes in sickle cell disease (SCD) patients compared with healthy controls. Black bars represent genes that were included in the predefined set of iron-regulated genes (see Online Table I) . White bars represent genes that were identified as signifcantly differentially expressed between the 3 iron clusters or were included to validate the microarray data. ALDH1A1 indicates aldehyde dehydrogenase 1A1; ECE1, endothelin converting enzyme 1; FTL1, ferritin light chain 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HMOX, heme oxygenase-1; IL6, interleukin-6; SAT2, spermidine/spermine N1-acetyltransferase family member 2; ST13, suppression of tumorigenicity 13; and TLR4, toll-like receptor 4.
that were the most differentially expressed are involved in the inflammasome complex pathway. Inflammasomes are key signaling platforms that detect pathogenic microorganisms and sterile stressors and that activate expression of the highly proinflammatory cytokines interleukin-1β (IL-1β), IL-18, and IL-6. 39 Activation of the TLR system leads to cellular priming and upregulation of NLRP3 and subsequently its activation. 39 Thus, TLR4 can act as a cofactor of inflammasome activation or induce proinflammatory cytokines, such as IL-6 via NF-κB activation. 26 Interestingly, the PBMC transcriptome of SCD patients resembles that of healthy volunteers exposed to the TLR4 ligand lipopolysaccharide, highlighting the same pathways we find associated with high iron trafficking in SCD. Pentraxin-3, the product of the PTX3 gene that is also highly expressed in our high iron trafficking group, is a humoral pattern recognition molecule related to CRP 40 that is associated with the duration of SCD painful crisis episodes. 19 Using the microarray-based gene discovery assay, we have linked several important inflammation and innate immunity genes for the first time to excessive iron trafficking.
The Q-PCR results indicate that PBMC cytokine gene expression is associated with high iron and is dramatically increased in SCD. The high correlation of TLR4, FTL, and IL-6 in SCD PBMC gene expression by Q-PCR validates and extends the results of the gene discovery assay ( Figure 2C) . The 2 log difference in mean expression of IL-6 between SCD patients and controls reinforces that high iron and high expression of proinflammatory genes are both associated with expression of known downstream inflammatory cytokines ( Figure 2D ). Plasma levels of IL-6 are high in SCD [20] [21] [22] 41 and increase further during acute complications. [25] [26] [27] 41 Most nucleated cells are capable of expressing and synthesizing IL-6, but activated monocytes and macrophages, notable constituents of the PBMC cell population in our experiments, 27 are the likeliest source of IL-6 detected in our assays. Monocyte TLR4 signaling has been reported to be augmented by intracellular iron, 5, 6, 42 and comparable mechanisms may be involved in the augmentation of TLR4 signaling in SCD. Our results combined with published data indicate that robust iron trafficking in SCD is associated with increased expression of important inflammatory cytokines.
A relationship between iron and inflammation is supported by our observation that SCD patients with an inborn defect of cellular iron export have more inflammation compared with other SCD patients. Ferroportin is the only known mammalian After 100 months, patients were censored. Log-rank test showed that survival of patients between CRP groups was significantly different (P=0.0017). Five-year mortality percentages for the low, intermediate, and high CRP groups were, respectively, 12.4%, 20.5%, and 25.8%. In a multivariate analysis, CRP was an independent predictor of mortality (see Table 2 ). Figure 3 . Patients with the ferroportin Q248H mutation which is associated with high retention of intracellular iron have higher levels of C-reactive protein (CRP) and interleukin-6. To assess relationship between intracellular iron and inflammation, we used available ferroportin Q248H mutation status. Patients were analyzed previously for ferroportin mutation status. 29 A and B, In the gene-expression part of the study (ClinicalTrials.gov identifier: NCT00072826), the 5 patients with a ferroportin Q248H mutation (GT and TT genotype) had a significant (P<0.05) higher plasma level of CRP, and log 10 interleukin-6 (IL-6) trended (P=0.08) to be higher compared with 19 patients with wild-type ferroportin (GG genotype).C and D, As a sensitivity analysis, we repeated this in a case-control study in selection of patients of the National Institutes of Health (NIH) sickle cell disease (SCD) cohort (ClinicalTrials.gov identifier: NCT00011648). Fourteen patients with Q248H mutation were matched on genotype and ferritin level. We found that the 14 patients with the mutation had a significant higher CRP and log10 il6 than the matched controls. Because the ferroportin Q248H is also associated with less sensitivity for hepcidin and hepcidin levels are strongly associated with ferritin levels in SCD, we decided to perform this last analysis only in patients with a ferritin level <1000 mg/dL. *P<0.05. January 16, 2015 iron exporter and is essential for cellular iron export. 43 The q248h mutation has an allele frequency of 2.2% to 13.4% in African populations and results in a significant increase of cellular iron accumulation compared with wild-type ferroportin. 28, 29 Two independent data sets show clearly higher IL-6 and CRP levels in the SCD patients with the ferroportin q248h mutation, suggesting a role of monocyte and macrophage intracellular iron in inflammation. For this study, we combined several observations in different subgroups of patients from a 12-year study evaluating the prevalence and outcome of secondary pulmonary hypertension in SCD (ClinicalTrials.gov identifier NCT00011648). The specimens from patients in the various subgroups were chosen based on availability of plasma or DNA biospecimens, primarily influenced by the year of enrollment. Plasma specimens tended to be depleted because of prior research utilization from those patients enrolled early in the 12-year study relative patients enrolled later. The IL-6 assays were performed on a subgroup of specimens from patients enrolled later in the study, with consequently shorter follow-up time and fewer events, and therefore IL-6 mortality analysis was not performed; conversely, the related inflammatory biomarker CRP was available for the entire cohort with long-term follow up. Microarray specimens were obtained in a subgroup of patients who volunteered for this additional study. It is possible that the composition of these subgroups, such as inclusion of HbSC double heterozygote patients for improved statistical power, may have affected our results, but where applicable, our sensitivity analysis restricted to only HbSS patients showed qualitatively similar results.
To our knowledge this is the first study showing a strong link between a molecular marker of inflammation and mortality in SCD. Inflammation is generally accepted to be active in SCD, but its pathogenesis has been poorly understood. CRP is a sensitive but nonspecific marker of inflammatory pathways, produced by the liver in response to proinflammatory cytokines IL-1, IL-6, and IL-17, 27 and associated with TLR signaling and inflammasome activation. Our finding of an independent association of CRP with early death suggests the importance of inflammation in the pathophysiology of SCD.
These results could explain how high intracellular iron could contribute to risk of early death.
The association of the hemolytic marker bilirubin with high iron cluster in our gene expression experiment suggests that hemolysis is one of the causes of high SCD PBMC iron. In SCD, vast amounts of heme are released during intravascular hemolysis 44, 45 ; heme augments TLR signaling in monocytes and macrophages probably by inducing intracellular ROS. 42, 46 Injection of heme induces an acute fatal inflammatory vasculopathy in a SCD mouse model involving the TLR4 pathway. 47, 48 Recently, it was shown that next to TLR4 activation, inflammasome-related proteins NLRP3 and caspase-1, which also showed up in our gene discovery experiment, are required for heme-induced inflammation in wild-type mice. 49 In humans with β-thalassemia, another hemoglobinopathy associated with a high rate of hemolysis, monocyte TLR4 expression, and CRP is increased as well. 50, 51 Interventions that blockade the hemolysis-ironinflammation axis, that is, heme scavenging by recombinant hemopexin, iron chelation, TLR4, or downstream proinflammatory cytokine inhibition, are all effective in animal models of SCD. 47, 48, [51] [52] [53] Because we now show comparable pathways are activated in human SCD as in the animal models, these interventions seem promising in human SCD as well.
Conclusions
The SCD PBMC transcriptome reflects high intracellular iron exposure, which is associated with inflammation and mortality. The associations found in this study support a hypothetical model in which PBMC iron promotes clinically significant inflammatory pathways, such as TLR system and the inflammasome, identifying important targets for potential pharmacological intervention. 
